Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 255 results for radiotherapy

  1. Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)

    Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.

  2. Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.

    scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder...

  3. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

  4. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development Reference number: GID-TA11199 Expected publication date: TBC

  5. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  6. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  7. Photodynamic therapy for bile duct cancer (HTG82)

    Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.

  8. Cyanoacrylate instillation for occlusion of parotid sinuses (HTG20)

    Evidence-based recommendations on cyanoacrylate instillation for occlusion of parotid sinuses. This involves injecting a solution of lipiodiol and cyanoacrylate via the sinus into the parotid gland, sealing the sinus.

  9. AlignRT for intracranial stereotactic radiosurgery (MIB147)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .

  10. Radiofrequency ablation for colorectal liver metastases (HTG208)

    Evidence-based recommendations on radiofrequency ablation for the treatment of colorectal liver metastases. This involves using heat to destroy cancer cells in the liver.

  11. Interstitial laser therapy for breast cancer (HTG55)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

  12. Endoscopic transsphenoidal pituitary adenoma resection (HTG14)

    Evidence-based recommendations on endoscopic transsphenoidal pituitary adenoma resection. This involves inserting a tube into the nostril towards the tumour base and removing the tumour using specialised surgical instruments.